HER-2阴性胃癌的分子靶向治疗

doi:10.3760/cma.j.issn.1673422X.2016.12.016

摘要/Abstract

摘要： 目前分子靶向治疗已成为胃癌研究领域的热点。人类表皮生长因子受体-2(HER-2)靶基因的发现及相关靶向治疗已在临床广泛应用，而HER-2阳性的发病人群＜20%。除HER-2外，针对肿瘤细胞生长、浸润及血管生成等的靶点和靶向治疗值得关注。一些分子靶向药物应用于临床并呈现良好的疗效，为HER-2阴性胃癌患者带来希望。

关键词: 胃肿瘤, 受体,表皮生长因子, 分子靶向治疗

Abstract: Molecular targeted treatment has become hotspot in the gastric cancer research. Human epidermal growth factor receptor-2(HER-2) target genes found to treatment has widely used in clinical practice, and HER-2 positive incidence of less than 20%. In addition to HER-2, understanding the molecular pathways that characterize in cell growth, invasion and angiogenesis of targets and targeted therapy are worthy for attention.There are some molecular targeted drugs have been used to treat tumors,and patients can benefit from the treatment which brings new hope for patients with HER-2 negative gastric cancer.

Key words: Stomach neoplasms, Receptor, epidermal growth factor, Molecular targeted therapy

彭湃, 易善永, 赵玲. HER-2阴性胃癌的分子靶向治疗[J]. 国际肿瘤学杂志, 2016, 43(12): 943-946.

PENG Pai, YI Shan-Yong, ZHAO Ling. Molecular targeted therapy for HER2 negative gastric cancer[J]. Journal of International Oncology, 2016, 43(12): 943-946.

参考文献

［1］ Ohtsu A,Shah MA,Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized，doubleblind，placebocontrolled phase Ⅲ study［J］. J Clin Oncol， 2011， 29(30): 39683976. DOI: 10.1200/JCO.2011.36.2236. ［2］ Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor2: an update on ramucirumab［J］. Expert Opin Biol Ther, 2013, 13（8）: 11871196. DOI: 10.1517/14712598.2013.810717. ［3］ Wilke H, Cutsem EV, Sang Cheul S, et al. RAINBOW: a global, phase Ⅲ, randomized, doubleblind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on firstline platinumand fluoropyrimidine containing combination therapy rainbow IMCL CP120922 (I4TIEJVBE) ［R/OL］. ［20140307］. http://meetinglibrary.asco.org/content/123363143. ［4］ Li J， Qin S， Xu J， et al． Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized， placebocontrolled， parallelarm，phase Ⅱ trial［J］． J Clin Oncol, 2013, 31(26): 32193225．DOI: 10.1200/JCO.2013.48.8585. ［5］ Geng R, Li J. Apatinib for the treatment of gastric cancer［J］. Expert Opin Pharmacother, 2015, 16(1): 117122. DOI: 10.1517/14656566. 2015.981526. ［6］ Xing CG, Zhu BS, Fan X, et al. Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice［J］.World J Gastroenterol, 2009, 15(40): 50445052. DOI: 10.3748/wjg.15.5044. ［7］ Doi T， Muro K， Boku N， et al． Multicenter phase Ⅱ study of everolimus in patients with previously treated metastatic gastric cancer［J］． J Clin Oncol, 2010, 28 (11): 19041910. DOI: 10.1200/JCO.2009.26.2923. ［8］ Shen YC, Li CP, Yen CJ, et al. Phase Ⅱ multicentered study of lowdose everolimus plus cisplatin and weekly 24hour infusion of highdose 5fluorouracil and leucovorin as firstline treatment for patients with advanced gastric cancer［J］. Oncology, 2014, 87(2): 104113. DOI: 10.1159/000362671. ［9］ Wu JG, Yu JW, Wu HB, et al． Expressions and clinical significances of cMet,pMet and E2f1 in human gastric carcinoma［J］．BMC Res Notes, 2014, 7: 6. DOI: 10.1186/1756050076. ［10］ Doshi S, Gisleskog PO, Zhang Y，et al． Rilotumumab exposureresponse relationship in patients with advanced or metastatic gastric cancer［J］. Clin Cancer Res, 2015, 21(11): 24532461. DOI: 10.1158/10780432.CCR141661. ［11］ Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as firstline treatment for gastric or oesophagogastric junction adenocarcinoma: an openlabel, dose deescalation phase 1b study and a doubleblind, randomised phase 2 study［J］. Lancet Oncol， 2014, 15(9): 10071018. DOI: 10.1016/S14702045(14)700233. ［12］ Catenacci DV， Henderson L， Xiao SY， et al．Durable completeresponse of metastatic gastric cancer with antiMet therapy followed by resistance at recurrence［J］. Cancer Discov, 2011, 1(7): 573579.DOI: 10.1158/21598290. ［13］ Cunningham D, Bang YJ, Tabernero J, et al. MetGastric: a randomized phase Ⅲ study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2negative and metpositive adenocarcinoma of the stomach or gastroesophageal junction［R/OL］. ［20140307］. http://meetinglibrary.asco.org/content/114845132. ［14］ Scagliotti GV, Novello S, von Pawel J. The emerging role of Met/HGF inhibitors in oncology［J］. Cancer Treat Rev, 2013, 39(7): 793801. DOI: 10.1016/j.ctrv.2013.02.001. ［15］ Shah MA， Wainberg ZA， Catenacci DV， et al．PhaseⅡstudy evaluating 2 dosing schedules of oral foretinib ( GSK1363089),cMet /VEGFR2 inhibitor,in patients with metastatic gastric cancer［J］. PLoS One, 2013, 8(3): e54014. DOI: 10.1371/journal.pone.0054014. ［16］ Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets［J］. Gut, 2012, 61(5): 673684．DOI: 10.1136/gutjnl2011301839. ［17］ Li J, Ye Y, Wang M, et al. The overexpression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5fluorouracil towards gastric cancer［J］. Tumour Biol， 2016， 37(5): 68816891. DOI: 10.1007/ s1327701544111. ［18］ Yamada Y, Kiyota N, Fuse N, et al. A phase Ⅰ study of sorafenib in combination with S1 plus cisplatin in patients with advancedgastric cancer［J］. Gastric Cancer, 2014, 17（1）: 161172. DOI: 10.1007/s1012001302479. ［19］ Bang YJ, Im SA, Lee KW, et al．Randomized, doubleblind phase Ⅱ trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxelin patients with recurrent or metastatic gastric cancer［J］. J Clin Oncol， 2015, 33(33): 38583865. DOI: 10.1200/JCO.2014.60.0320. ［20］ Muro K, Chung HC, Shankaran V,et al．Pembrolizumab for patients with PDL1positive advanced gastric cancer(KEYNOTE012): a multicentre, openlabel, phase 1b trial［J］. Lancet Oncol, 2016, 17(6): 717726. DOI: 10.1016/S14702045(16)001753.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[10]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[11]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[12]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[13]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[14]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[15]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.